Clinical Trials Sponsored by DARA Therapeutics

Total 8725 results

DARA Therapeutics

Completed

Neuropathic Pain in Patients With Cancer

Neuropathic Pain

United States, Puerto Rico
Cara Therapeutics, Inc.

Completed

Study to Evaluate the Efficacy and Safety of Oral Difelikefalin (CR845) for Moderate to Severe Pruritus in Subjects With Notalgia Paresthetica (KOMFORT)

Pruritus | Notalgia Paresthetica

United States, Canada
Cara Therapeutics, Inc.

Approved for marketing

Intermediate-Size Patient Population Expanded Access Program for Intravenous Difelikefalin

Uremic Pruritus
Cara Therapeutics, Inc.

Completed

CR845-CLIN3103: A Global Study to Evaluate the Safety and Efficacy of CR845 in Hemodialysis Patients With Moderate-to-Severe Pruritus (KALM-2)

Uremic Pruritus

United States, Canada, Czechia, Australia, Germany, Hungary, Korea, Republic of, New Zealand, Poland, Taiwan, United Kingdom
Cara Therapeutics, Inc.

Completed

Study to Evaluate IV CR845 in Hemodialysis Patients With Moderate-to-Severe Pruritus

Uremic Pruritus

United States
Cara Therapeutics, Inc.

Completed

A Study Evaluating the Overall Pain Relief and Safety of Intravenous (IV) CR845 in Patients Undergoing Abdominal Surgery

Post Abdominal Surgery Pain

United States
Cara Therapeutics, Inc.

Completed

Study to Evaluate Analgesic Effect of IV Administration of Kappa Agonist CR845 For Hysterectomy Surgery

Postoperative Pain

United States
Dart Therapeutics. LLC

Completed

DART Electrical Impedance Myography (EIM) Trial in Duchenne Muscular Dystrophy (DMD) and Healthy Controls

Duchenne Muscular Dystrophy

United States
Cara Therapeutics, Inc.

Recruiting

CR845-310302: A Study to Evaluate the Safety and Efficacy of Difelikefalin in Advanced Chronic Kidney Disease Patients With Moderate-to-Severe Pruritus

Chronic Kidney Diseases | Pruritus

United States, Korea, Republic of, Australia, Bulgaria, Germany, Hungary, Italy, Poland, Romania, Spain, Argentina, Brazil, Mexico
Cara Therapeutics, Inc.

Completed

CR845-100303: Study to Assess the Potential of Physical Withdrawal From Intravenous CR845 (Difelikefalin) in Hemodialysis Patients

Hemodialysis

United States
Cara Therapeutics, Inc.

Completed

CR845-CLIN3105: A Study to Evaluate the Safety and Effectiveness of CR845 in Hemodialysis Patients With Moderate-to-Severe Pruritus

Uremic Pruritus

United States, Czechia, Hungary, Poland
Cara Therapeutics, Inc.

Completed

Extension Study to Evaluate IV CR845 in Hemodialysis Patients With Moderate-to-Severe Pruritus

Uremic Pruritus

United States, Puerto Rico
Cara Therapeutics, Inc.

Completed

Study to Evaluate the Pharmacokinetics and Metabolism of [14C] CR845 (Difelikefalin) in Patients With End Stage Renal Disease on Hemodialysis and in Healthy Subjects

Healthy | Hemodialysis

United States
Cara Therapeutics, Inc.

Recruiting

Study to Evaluate the Efficacy and Safety of Oral Difelikefalin for Moderate to Severe Pruritus in Subjects With Notalgia Paresthetica

Pruritus | Notalgia Paresthetica

United States, Poland, Spain, Canada, Germany
Cara Therapeutics, Inc.

Recruiting

A Study to Evaluate the Safety and Efficacy of Difelikefalin in Advanced Chronic Kidney Disease Patients With Moderate-to-Severe Pruritus

Chronic Kidney Diseases | Pruritus

United States
Cara Therapeutics, Inc.

Terminated

Study to Evaluate the Efficacy and Safety of Oral Difelikefalin as Adjunct Therapy to a Topical Corticosteroid for Moderate to Severe Pruritus in Subjects With Atopic Dermatitis (KIND-1)

Pruritus | Atopic Dermatitis

United States
Cara Therapeutics, Inc.

Completed

A Study to Evaluate the Safety and Efficacy of CR845 in Chronic Kidney Disease Patients With Moderate-to-Severe Pruritus

Chronic Kidney Diseases | Pruritus

United States
Cara Therapeutics, Inc.

Terminated

Study to Evaluate the Safety and Efficacy of Oral CR845 (Difelikefalin) in Patients With Primary Biliary Cholangitis (PBC) and Moderate-to-Severe Pruritus

Cholestatic Pruritus

United States
Cara Therapeutics, Inc.

Completed

A Study to Evaluate the Safety and Efficacy of CR845 in Hemodialysis Patients With Moderate-to-Severe Pruritus (KALM-1)

Uremic Pruritus

United States
Cara Therapeutics, Inc.

Completed

Study to Evaluate the Efficacy and Safety of Oral Difelikefalin (CR845) for Moderate to Severe Pruritus in Subjects With Atopic Dermatitis (KARE)

Pruritus | Atopic Dermatitis

United States, Canada
Cara Therapeutics, Inc.

Completed

A Study Evaluating Pain Relief and Safety of Orally Administered CR845 in Patients With Osteoarthritis of Hip or Knee

Arthritis | Joint Diseases | Musculoskeletal Diseases | Rheumatic Diseases | Osteoarthritis, Knee | Osteoarthritis, Hip

United States
Cara Therapeutics, Inc.

Completed

Study to Investigate the Effects of Single Intravenous Doses of Difelikefalin (CR845) on the QTc Interval in Healthy Subjects

Healthy

United States
Cara Therapeutics, Inc.

Completed

A Study of the Safety and Effectiveness of Orally Administered CR845 in Patients With Osteoarthritis of the Hip or Knee

Osteoarthritis

United States
Cara Therapeutics, Inc.

Completed

Safety and Pharmacokinetics of IV CR845 in Hemodialysis Patients, and Its Efficacy in Patients With Uremic Pruritus

Pruritus | Uremic Pruritus

United States
Cara Therapeutics, Inc.

Completed

Study to Evaluate Analgesic Effect of Intravenous Administration of Kappa Agonist CR845 After Hysterectomy Surgery

Acute Pain

United States
Cara Therapeutics, Inc.

Completed

A Phase 2 Study to Evaluate Analgesic Effect of IV CR845 For Pain Following Bunionectomy Surgery

Acute Pain

United States
Dana-Farber Cancer Institute
Celldex Therapeutics

Recruiting

NeoVax + CDX-301 and Nivolumab or Pembrolizumab in Melanoma

Melanoma | Metastatic Melanoma

United States
Fate Therapeutics
Dana-Farber Cancer Institute

Completed

Safety and Efficacy of ProHema Modulated Umbilical Cord Blood Units in Subjects With Hematologic Malignancies.

Hematologic Malignancies | Allogeneic Stem Cell Transplantation

United States
Dana-Farber Cancer Institute
Partner Therapeutics (PTx)

Withdrawn

Sargramostim (GM-CSF) + PD-1

Metastatic Melanoma | Unresectable Melanoma | Stage IV Melanoma | Stage III Melanoma

United States
Dana-Farber Cancer Institute
Kazia Therapeutics Limited

Recruiting

GDC-0084 in Combination With Trastuzumab for Patients With HER2-Positive Breast Cancer Brain Metastases

Breast Cancer

United States
Dana-Farber Cancer Institute
Stemline Therapeutics, Inc.

Recruiting

SL-401 in Combination With Azacitidine or Azacitidine/Venetoclax in Acute Myeloid Leukemia (AML), High-Risk Myelodysplastic Syndrome (MDS) or Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN)

Acute Myeloid Leukemia | Myelodysplastic Syndrome | Blastic Plasmacytoid Dendritic Cell Neoplasm

United States
Medical University of South Carolina
Dart Therapeutics. LLC

Recruiting

Low-Intensity Focused Ultrasound for Treatment-Resistant Depression

Major Depressive Disorder | Treatment Resistant Depression

United States
Shayna Sarosiek, MD
ADC Therapeutics S.A.

Recruiting

Loncastuximab Tesirine in WM

Waldenstrom Macroglobulinemia

United States
Glenn J. Hanna
Actuate Therapeutics Inc.

Active, not recruiting

9-ING-41 Plus Carboplatin in Salivary Gland Carcinoma

Adenoid Cystic Carcinoma | Metastatic Cancer | Salivary Gland Cancer | Recurrent Salivary Gland Cancer

United States
Ranok Therapeutics (Hangzhou) Co., Ltd.

Recruiting

A Study of RNK05047 in Subjects With Advanced Solid Tumors/Diffuse Large B-cell Lymphoma (CHAMP-1)

Advanced Solid Tumor | DLBCL

United States
Lakshmi Nayak, MD
Kazia Therapeutics Limited

Recruiting

Paxalisib (GDC-0084) In Recurrent Or Refractory PCNSL

Primary Central Nervous System Lymphoma | Non-Hodgkin Lymphoma of Extranodal Site

United States
Guru P. Sonpavde
QED Therapeutics, Inc.

Withdrawn

Phase I BLASST-3 Trial ((BLASST)-3)

Bladder Cancer | Bladder Transitional Cell Carcinoma | Fibroblast Growth Factor Receptor
Dana-Farber Cancer Institute
Vascular Biogenics Ltd. operating as VBL Therapeutics

Active, not recruiting

VB-111 in Surgically Accessible Recurrent/Progressive GBM

Glioblastoma | Recurrent Glioblastoma

United States
Dana-Farber Cancer Institute
Novartis; Pediatric Oncology Experimental Therapeutics Investigators' Consortium

Completed

Everolimus (RAD001) for Children With Chemotherapy-Refractory Progressive or Recurrent Low-Grade Gliomas

Glioma | Astrocytoma | Low-grade Glioma

United States
Akebia Therapeutics
Cyclerion Therapeutics

Completed

A Study to Evaluate the Soluble Guanylate Cyclase (sGC) Stimulator IW-1973 in Diabetic Nephropathy / Diabetic Kidney Disease as Measured by Albuminuria

Type 2 Diabetes Mellitus With Diabetic Nephropathy

United States
Akebia Therapeutics
Cyclerion Therapeutics

Completed

A Study of the Effect of IW-1973 on the Exercise Capacity of Patients With Heart Failure With Preserved Ejection Fraction (HFpEF) (CAPACITY-HFpEF)

Heart Failure With Preserved Ejection Fraction

United States, Canada
Dana-Farber Cancer Institute
National Institutes of Health (NIH); Candel Therapeutics, Inc.

Recruiting

A Study of the Treatment of Recurrent Malignant Glioma With rQNestin34.5v.2 (rQNestin)

Glioma | Glioblastoma | Astrocytoma | Malignant Glioma of Brain | Brain Cancer | Brain Tumor | Glioblastoma Multiforme | Ependymoma | Ganglioglioma | Oligodendroglioma | Malignant Astrocytoma | Anaplastic Oligodendroglioma of Brain (Diagnosis) | Mixed Oligo-Astrocytoma | Pylocytic/Pylomyxoid Astrocytoma

United States
CRISPR Therapeutics AG

Recruiting

A Safety and Efficacy Study Evaluating CTX131 in Adult Subjects With Relapsed or Refractory Solid Tumors

Clear Cell Renal Cell Carcinoma | Pancreatic Adenocarcinoma | Cervical Carcinoma | Malignant Pleural Mesothelioma | Esophageal Carcinoma

United States
CRISPR Therapeutics AG

Active, not recruiting

A Safety and Efficacy Study Evaluating CTX130 in Subjects With Relapsed or Refractory T or B Cell Malignancies (COBALT-LYM)

T Cell Lymphoma

United States, Australia, Canada
CRISPR Therapeutics AG

Active, not recruiting

A Safety and Efficacy Study Evaluating CTX110 in Subjects With Relapsed or Refractory B-Cell Malignancies (CARBON)

B-cell Lymphoma | Non-Hodgkin Lymphoma | B-cell Malignancy | Adult B Cell ALL

United States, Spain, Canada, France, Germany, Australia
Bacainn Therapeutics, Inc.

Completed

A Phase 1, Single-Ascending-Dose Study of BT051 in Healthy Subjects

Healthy Volunteers

United States
Celsus Therapeutics PLC

Terminated

Double-Blind, Trial to Evaluate the Safety and Efficacy of MRX-6 Cream 2% (C012013)

Atopic Dermatitis

Israel
Eikon Therapeutics
Impact Therapeutics, Inc.

Recruiting

A First-in-human Study of PARP1 Selective Inhibitor, IMP1734, in Participants With Advanced Solid Tumors

Advanced Solid Tumor

Australia, United States
APRINOIA Therapeutics, LLC

Active, not recruiting

A First-in-Human Study to Assess Single Doses of APNmAb005 in Healthy Participants

Alzheimer Disease | Tauopathies | Healthy Volunteers

United States
CRISPR Therapeutics AG

Active, not recruiting

A Safety and Efficacy Study Evaluating CTX130 in Subjects With Relapsed or Refractory Renal Cell Carcinoma (COBALT-RCC)

Renal Cell Carcinoma

United States, Australia, Canada, Netherlands

Clinical Trials Sponsored by DARA Therapeutics

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in South Korea

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations